Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;15(1):8485.
doi: 10.1038/s41467-024-52918-x.

The molecular dissection of TRIM25's RNA-binding mechanism provides key insights into its antiviral activity

Lucía Álvarez #  1 , Kevin Haubrich #  1 , Louisa Iselin  2   3   4 , Laurent Gillioz  5 , Vincenzo Ruscica  4 , Karine Lapouge  6 , Sandra Augsten  1 , Ina Huppertz  7 , Nila Roy Choudhury  8   9 , Bernd Simon  1   10 , Pawel Masiewicz  1 , Mathilde Lethier  11 , Stephen Cusack  11 , Katrin Rittinger  12 , Frank Gabel  13 , Alexander Leitner  14 , Gracjan Michlewski  8   9 , Matthias W Hentze  7 , Frédéric H T Allain  5 , Alfredo Castello  15 , Janosch Hennig  16   17
Affiliations

The molecular dissection of TRIM25's RNA-binding mechanism provides key insights into its antiviral activity

Lucía Álvarez et al. Nat Commun. .

Abstract

TRIM25 is an RNA-binding ubiquitin E3 ligase with central but poorly understood roles in the innate immune response to RNA viruses. The link between TRIM25's RNA binding and its role in innate immunity has not been established. Thus, we utilized a multitude of biophysical techniques to identify key RNA-binding residues of TRIM25 and developed an RNA-binding deficient mutant (TRIM25-m9). Using iCLIP2 in virus-infected and uninfected cells, we identified TRIM25's RNA sequence and structure specificity, that it binds specifically to viral RNA, and that the interaction with RNA is critical for its antiviral activity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. NMR and ITC analysis of RNA binding by TRIM25 PRY/SPRY domain.
a Domain arrangement of TRIM25. b 1H-15N-HSQC spectra of 100 µM 15N-labelled TRIM25 PRY/SPRY domain free (dark blue) and in presence of different ratios of pre-let-7 RNA (1:1 light blue, 1:2 green and 1:3 yellow). c Significant CSPs from the titration of TRIM25 PRY/SPRY with pre-let-7 plotted on the structure (PDB: 6FLM) indicate two binding sites (binding site 1 coloured red, binding site 2 coloured blue). The structure shown was generated using UCSF ChimeraX. d Histograms of chemical shift perturbations (CSPs) for TRIM25-PRY/SPRY upon binding to full-length pre-let-7 (top), pre-let-7-loop (middle) and pre-let-7-stem (bottom). The continuous line shows the average CSP and the dashed line indicates the average plus one standard deviation. Residues for which the CSPs are more than one standard deviation above the average are shown in open bars. Significantly affected regions are indicated in the protein sequence by red and blue horizontal bars. The RNA is coloured according to where it binds in the PRY/SPRY domain (binding site 1 in red, binding site 2 in blue). Source data are provided as a Source Data file. e Representative ITC binding isotherm for TRIM25 PRY/SPRY:pre-let-7 complex (n = 4). The value shown in the figure is the average of all replicates and its standard deviation. f Representative ITC binding isotherm for TRIM25 PRY/SPRY triple mutant (m3): pre-let-7 complex (n = 3). All experimental setups and results of ITC measurements including replicates can be found in Supplementary Table 1.
Fig. 2
Fig. 2. ITC and CLIR-MS/MS analysis of RNA binding by TRIM25 CC domain.
a Representative ITC binding isotherm for TRIM25 CC:pre-let-7 complex (n = 3). The value shown in the figure is the average of all replicates and its standard deviation. b The surface potential representation of the CC dimer (PDB:4LTB) indicates a positively charged surface. The enlargement of this interface shows potential RNA binding residues. Mutation of residues K283 and K285, shown in grey, leads to a TRIM25-CC mutant we term m2. In purple, the peptide detected by CLIR-MS/MS (see below) is highlighted including the four potential RNA binding residues. Mutation of these four residues leads to a TRIM25-CC mutant we term m4. The structure shown was generated using UCSF ChimeraX. c Representative ITC binding isotherm for TRIM25 CC-m2 with pre-let-7 complex (n = 3). d Schematic representation of the CLIR-MS/MS method. The RNA binding protein (grey) is crosslinked to an equimolar mixture of unlabelled (black) and uniformly 13C/15N-labelled RNA (red). e MS spectrum of the TRIM25-derived peptide GISTKPVYIPEVELNHK crosslinked to a single U nucleotide (see methods). f Representative ITC binding isotherm for TRIM25 CC-m4:pre-let-7 complex (n = 3). All experimental setups and ITC measurements including replicates are listed in Supplementary Table 1.
Fig. 3
Fig. 3. CC and PRY/SPRY domains bind RNA cooperatively.
a Representative ITC binding isotherm for TRIM25 CC-PRY/SPRY (n = 3). The value shown is the average of all replicates and its standard deviation. b 1H,15N-HSQC spectra comparing CC-PRY/SPRY in the absence (black) and presence (red) of pre-let-7. The strong signal loss of peaks corresponding to residues in structured regions of the PRY/SPRY domain upon addition of equimolar amounts of pre-let-7 indicates that the RNA keeps the PRY/SPRY domain at the CC interface leading to joint tumbling and thus increased transverse relaxation and line broadening beyond detection. c Proposed mechanisms of RNA-induced conformational change. CC and PRY/SPRY of TRIM25 interact only transiently in the absence of RNA. Binding of stem-loop RNA stabilizes the interaction between the two domains. CC-PRY/SPRY dimer structure (PDB: 6FLN) shown as a surface representation with two binding sites in the PRY/SPRY domain (binding site 1 coloured red and binding site 2 coloured blue) and the binding site in the CC domain (coloured purple). The structure shown was generated using UCSF ChimeraX. In a second possibility, the stem-loop RNA is sandwiched between the CC and PRY/SPRY domains, which do not interact with each other. d SAXS curves and pairwise distance distributions for free TRIM25 CC-PRY/SPRY (black) and its complex with pre-let-7 RNA (red). The distance distribution of the free protein has two maxima, indicating independent tumbling of the CC and PRY/SPRY domains, whereas the distribution for the RNA-bound complex is much narrower and contains only one peak, indicating a conformational change towards a more compact form. e CC-PRY/SPRY dimer structure (PDB: 6FLN) in cartoon representation showing all RNA binding sites in the PRY/SPRY domain (binding site 1, red and binding site 2, blue), and CC domain (purple) and residues mutated to obtain the TRIM25 CC-PRY/SPRY m9 mutant. f Representative ITC binding isotherm for the TRIM25 CCPRY/SPRY-m9:pre-let-7 complex (n = 3). All experimental setups and ITC measurements including replicates are provided in Supplementary Table 1.
Fig. 4
Fig. 4. iCLIP2 analysis of TRIM25 reveals structural and sequence signatures in target RNAs.
iCLIP2 was applied to HEK293 TRIM25 KO Flip-In expressing TRIM25-WT or the different TRIM25 mutants (m3 or m9) and infected with SINV and harvested 9 hour-post-infection, hpi (inf.) or mock-infected (mock). a Bar plots showing the number of cellular RNA binding sites (purple) and target gene (green) counts identified for the different samples. b Intersection plot comparing the different cellular targets RNAs identified in the different samples. c Density plot showing the distribution of binding sites across 5’ UTRs, CDSs and 3’ UTRs on cellular target RNAs for the different samples. d Percentage of paired and unpaired sequences across the binding site for the mock WT sample (see Supplementary Fig. 4f for TRIM25-WT infected sample). e Motifs enriched in the cellular RNA binding sites of the WT mock and SINV infected samples can be clustered into two prominent classes, an AGAA motif (motif 1) and a UGG motif (motif 2). f Density plot showing the distribution of the sequence motifs across the binding site for the TRIM25-WT mock and infected samples (green for motif 1 and orange for motif 2). The dotted line indicates the peak in the crosslinking signal. g Binding profile of TRIM25-WT on SINV RNA. Significant binding sites (p < 0.01) are indicated as blue boxes underneath the binding site density plot. h Secondary structure of the binding sites using SHAPE data. The colour of the nucleotides indicates the cross-linking density at each nucleotide position. The line surrounding the nucleotide indicates the presence of the identified motifs in the RNA structure (green for motif 1 and orange for motif 2).
Fig. 5
Fig. 5. Impact of the RNA binding activity of TRIM25 on its antiviral activity.
a Red fluorescence signal in TRIM25 WT (black) and mutant lines (m3 in blue, m9 in orange and E3-dead in purple) infected with SINV-mCherry (left panel) or SINV-nsp3-mScarlet (right panel). Fluorescence was measured every 15 min in a plate reader with atmospheric control (5% CO2 and 37 °C). The fluorescence is represented as mean ± SD of six independent infections in three biological replicates. Statistical differences are based on a two-tailed homoscedastic t-test (***p < 0.001; **p < 0.01; *p < 0.05). No adjustments were made for multiple comparisons. b Localization analysis by immunofluorescence and smFISH of TRIM25 (green) and SINV RNA (red). Nuclei are labelled with DAPI. Green and red fluorescence profiles for regions of interest are displayed on the right.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Takeuchi, O. & Akira, S. Innate immunity to virus infection. Immunol. Rev.227, 75–86 (2009). - PMC - PubMed
    1. Deng, Y., Wang, Y., Li, L., Miao, E. A. & Liu, P. Post-Translational Modifications of Proteins in Cytosolic Nucleic Acid Sensing Signaling Pathways. Front Immunol.13, 898724 (2022). - PMC - PubMed
    1. Zinngrebe, J., Montinaro, A., Peltzer, N. & Walczak, H. Ubiquitin in the immune system. EMBO Rep.15, 28–45 (2014). - PMC - PubMed
    1. Jiang, X. & Chen, Z. J. The role of ubiquitylation in immune defence and pathogen evasion. Nat. Rev. Immunol.12, 35–48 (2012). - PMC - PubMed
    1. Davis, M. E. & Gack, M. U. Ubiquitination in the antiviral immune response. Virology479–480, 52–65 (2015). - PMC - PubMed

MeSH terms

LinkOut - more resources